Brachial Plexus Tolerance To Standard Fractionation Re-irradiation
K. Dibs,E. Gogineni,D.L. Mitchell,D.J. Konieczkowski,S. Baliga,S.R. Jhawar,J.D. Palmer,D.M. Blakaj
DOI: https://doi.org/10.1016/j.ijrobp.2024.01.128
IF: 8.013
2024-04-01
International Journal of Radiation Oncology*Biology*Physics
Abstract:Purpose/Objective(s) Head and neck re-irradiation treatment approach can lead to various side effects like radiation induced brachial plexopathy (RIBP). Factors contributing to brachial plexus injury in the re-irradiation setting need further assessment. We aim to identify these factors to help tailor treatment management. Materials/Methods 71 BP sites with 48 patients (pts), treated with re-irradiation between 2015 and 2022 for recurrent head and neck cancer, were assessed. Reverse Kaplan-Meier and logistic regression were used to test the correlation between variables and outcomes. Common terminology criteria of adverse events (CTCAE v5.0) was used to define brachial plexus injury. Results The median age of pts was 65 (range, 29-79), 65% of pts were males, and 88% had ECOG performance status of 0-1. All pts received 1.64-2.12 Gy per fraction with one fraction per day and 5 fractions per week via VMAT. 15% additionally received IORT during salvage treatment ranging from 10-15Gy. 27% of patients in the first course and 88% in the second course of pts had surgery, with RT delivered in the adjuvant setting; the remainder had definitive-intent radiation without surgery. Concurrent chemotherapy was delivered to 67% of pts in the first course (Cisplatin 40%, Cetuximab 17%, Carboplatin +/- Paclitaxel 10%) and 62% in the second course (Carboplatin/Paclitaxel 38%, Cisplatin 16%, Cetuximab 6%, Nivolumab 2%). The median duration between RT courses was 34 months (4.6-216). With a median follow-up of 20.1 months, the cumulative incidence of RIBP at 1- and 2- year for the whole cohort was 9% and 17%, respectively. The cumulative incidence of RIBP was lower in pts with a cumulative Dmax of less than 116Gy, (1-year: 2% vs 22%, p <.001), Dmean of less than 70Gy, (1-year: 4% vs 18%, p .003). When V80 less than 1.9cc, V90 less than 1.5cc and V100 less than 1.3cc, the 1-year cumulative incidence of RIBP was 3% vs 18% p .004, 2% vs 20% p 0.001, and 6% vs 18% p .023, respectively. The 1- year cumulative incidence of RIBP in correlation with concurrent cisplatin was 62% vs 3%, p <.001. 1- year cumulative incidence of RIBP with age less than 65 was 18% vs 2%, p .002. 1-year cumulative incidence of RIBP with positive neck lymph node was 22% vs 3% p <.001. On multivariate analysis, age below 65 (HR 9.7 [CI 1.7-57], p .012), Dmax above 116Gy (HR 23 [CI 2.2-245], p .009) and positive neck lymph node during second radiation (HR 6.1 [CI 1.1-33], p .039] continued to show increasing risk of RIBP. Conclusion RIBP was higher in younger pts, pts received concurrent cisplatin during the 2nd course, positive neck lymph node, cumulative Dmax 116Gy, mean 70Gy, V80 1.9cc, V90 1.5cc and V100 1.3cc. We identified 10 cases with brachial plexopathy. six pts had grade I, 3 pts had grade II and one pt had grade III brachial plexopathy. Median time to develop RIBP was 9.5 months (range, 1-17.1). Prospective study, longer follow up, and higher numbers are warranted.
oncology,radiology, nuclear medicine & medical imaging